Alagorie AR, Nittala MG, Velaga S, et al. - In this post hoc analysis of a randomized clinical trial, researchers sought to explore the correlation of intravitreal aflibercept with changes in macular vascular density utilizing optical coherence tomography angiography in patients with proliferative diabetic retinopathy without diabetic macular edema. They analyzed data on 40 eyes of 40 individuals with proliferative diabetic retinopathy without diabetic macular edema who were enlisted in the Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy clinical trial from August 1, 2016, to June 31, 2017. After 12 months of intravitreal aflibercept therapy, macular vascular density did not change. This result may reflect a beneficial association between anti-vascular endothelial growth factor therapy and macular vascular density since nonperfusion is expected to progress in diabetic retinopathy.